118 related articles for article (PubMed ID: 14630086)
1. p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22).
Cividin M; Brizard F; Sorel N; Renaud M; Guilhot F; Brizard A
Leuk Res; 2004 Jan; 28(1):97-9. PubMed ID: 14630086
[TBL] [Abstract][Full Text] [Related]
2. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.
Albano F; Anelli L; Zagaria A; Coccaro N; Casieri P; Rossi AR; Vicari L; Liso V; Rocchi M; Specchia G
Mol Cancer; 2010 May; 9():120. PubMed ID: 20500819
[TBL] [Abstract][Full Text] [Related]
3. Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Godley LA
Leuk Lymphoma; 2009 Jun; 50(6):871-2. PubMed ID: 19479615
[No Abstract] [Full Text] [Related]
4. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
Kubota Y; Waki M
Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
[No Abstract] [Full Text] [Related]
5. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?
Roumier C; Daudignon A; Soenen V; Dupriez B; Wetterwald M; Lai JL; Cosson A; Fenaux P; Preudhomme C
Haematologica; 1999 Dec; 84(12):1075-80. PubMed ID: 10586207
[TBL] [Abstract][Full Text] [Related]
6. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
[TBL] [Abstract][Full Text] [Related]
7. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
Miglino M; Varaldo R; Colombo N; Grasso R; Clavio M; Garuti A; Aquino S; Albarello A; Sessarego M; Gobbi M
J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
[TBL] [Abstract][Full Text] [Related]
8. p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16).
Dai HP; Xue YQ; Wu LL; Pan JL; Gong YL; Wu YF; Zhang J; Wu DP; Chen SN
Int J Hematol; 2012 Dec; 96(6):814-7. PubMed ID: 23054652
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
[TBL] [Abstract][Full Text] [Related]
11. Acute megakaryoblastic leukaemia with extreme thrombocytosis and p190(bcr/abl)rearrangement.
Balatzenko G; Guenova M; Zechev J; Toshkov S
Ann Hematol; 2004 Jun; 83(6):381-5. PubMed ID: 14615910
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Sun X; He Y; Mao C; Zhu L; Qin X; Huang S
Leuk Lymphoma; 2014 Feb; 55(2):435-8. PubMed ID: 23772664
[No Abstract] [Full Text] [Related]
13. Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
Zámecníkova A; Al Bahar S; Ramesh P
Cancer Genet Cytogenet; 2008 Jun; 183(2):109-13. PubMed ID: 18503829
[TBL] [Abstract][Full Text] [Related]
14. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Kurzrock R; Kantarjian HM; Druker BJ; Talpaz M
Ann Intern Med; 2003 May; 138(10):819-30. PubMed ID: 12755554
[TBL] [Abstract][Full Text] [Related]
15. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
16. Complex chromosome 9, 20, and 22 rearrangements in acute lymphoblastic leukemia with duplication of BCR and ABL sequences.
Stevens-Kroef MJ; Dirckx R; Meers LE; Albrechts JC; Schouten HC; Hamers AJ
Cancer Genet Cytogenet; 2000 Jan; 116(2):119-23. PubMed ID: 10640143
[TBL] [Abstract][Full Text] [Related]
17. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
[TBL] [Abstract][Full Text] [Related]
18. Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
Pieńkowska-Grela B; Rygier J; Woroniecka R; Grygalewicz B; Pastwińska A; Krawczyk P; Ceglerek B; Seferyńska I; Sikorska A; Konopka L
Leuk Lymphoma; 2009 Jun; 50(6):952-65. PubMed ID: 19479611
[TBL] [Abstract][Full Text] [Related]
19. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
[TBL] [Abstract][Full Text] [Related]
20. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
